z-logo
Premium
Osteosarcoma in children 5 years of age or younger at initial diagnosis
Author(s) -
Worch Jennifer,
Matthay Katherine K.,
Neuhaus John,
Goldsby Robert,
DuBois Steven G.
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22509
Subject(s) - medicine , osteosarcoma , confidence interval , hazard ratio , young adult , amputation , pediatrics , surgery , pathology
Background Since osteosarcoma is extremely rare in children ≤5 years of age, we sought to investigate if tumor characteristics, treatment strategies, and outcomes differ compared to older patients. Procedure Patients <20 years of age with high‐grade osteosarcoma reported to national SEER database from 1973 to 2006 were separated into two groups based on age at diagnosis: ≤5 years (n = 49) and 6–19 years (n = 1,687). Patient, tumor, and treatment characteristics were compared using Fisher exact tests. Overall survival was estimated by Kaplan–Meier methods and compared using log‐rank tests and Cox models. Results Patients ≤5 years had higher proportions of osteosarcoma arising from the upper limb compared to older patients (24.5% vs. 11.2%; P  = 0.006). These very young patients had a significantly higher proportion of telangiectatic histology (10.2% vs. 2.9%; P  = 0.017). Sex, metastatic status, race, or ethnicity did not differ by age. A higher proportion of very young patients was treated with amputation (55.2% vs. 27.3%; P  = 0.002). Five‐year overall survival was inferior for patients with localized osteosarcoma 5 years of age or younger compared to older children (51.9% vs. 67.3%; P  = 0.03). After controlling for metastatic status, year of diagnosis, and tumor site, the hazard ratio for death in very young patients was 1.6 (95% confidence interval 1.02–2.36; P  = 0.04) compared to older patients. Conclusions Tumor characteristics, treatment, and outcomes differ among children ≤5 years of age compared to older pediatric patients. These differences may reflect differences in tumor biology. Pediatr Blood Cancer. 2010;55:285–289. © 2010 Wiley–Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom